Related Experiment Video

Updated: Jun 20, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Secondary prevention strategies for coronary heart disease

Shepard D Weiner1, LeRoy E Rabbani

  • 1Division of Cardiology, Department of Medicine, Columbia University Medical Center-New York Presbyterian Hospital, 161 Fort Washington Avenue, NewYork, NY 10032, USA.

Journal of Thrombosis and Thrombolysis
|August 21, 2009
PubMed

Insights

Optimizing secondary prevention for coronary heart disease (CHD) is crucial. Implementing evidence-based therapies, including antiplatelet treatments, can significantly reduce cardiovascular events and save lives.

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Thrombosis Research

Background:

  • Patients with established coronary heart disease (CHD) face a high risk of subsequent cardiovascular events.
  • Despite improvements, adherence to evidence-based secondary prevention therapies for CHD remains suboptimal.
  • Mortality from CHD has decreased due to risk factor reduction and evidence-based therapies, yet optimization could save more lives.

Purpose of the Study:

  • To review the epidemiology and risk assessment of CHD.
  • To discuss current pharmacologic and nonpharmacologic secondary prevention strategies for CHD.
  • To summarize guidelines and evidence supporting treatment options, with an emphasis on antiplatelet therapy.

Main Methods:

  • Review of epidemiological data on CHD.
  • Analysis of current pharmacologic and nonpharmacologic secondary prevention strategies.
  • Summary of American College of Cardiology (ACC) and American Heart Association (AHA) guidelines.
  • Emphasis on the role of antiplatelet therapy in preventing cardiovascular events.

Main Results:

  • Optimization of secondary prevention strategies has the potential to save numerous lives annually in the US.
  • Evidence-based medical therapies and risk factor reduction have contributed to decreased CHD mortality.
  • Antiplatelet therapy plays a critical role in managing thrombosis and preventing clinical cardiovascular events.

Conclusions:

  • Enhanced implementation of secondary prevention strategies is vital for reducing cardiovascular morbidity and mortality.
  • Current guidelines emphasize a comprehensive approach to CHD secondary prevention.
  • Further focus on therapies like antiplatelet agents is essential for improving patient outcomes.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Preventive Healthcare Services01:30

Preventive Healthcare Services

Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...